Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2020

Open Access 01-12-2020 | Parkinson's Disease | Research article

Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

Authors: Anna Santaella, H. Bea Kuiperij, Anouke van Rumund, Rianne A. J. Esselink, Alain J. van Gool, Bastiaan R. Bloem, Marcel M. Verbeek

Published in: BMC Neurology | Issue 1/2020

Login to get access

Abstract

Background

Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.

Methods

CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed.

Results

Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01).

Conclusions

PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.
Appendix
Available only for authorised users
Literature
1.
2.
Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004;56(4):532–9.PubMedCrossRef
3.
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211.PubMedCrossRef
4.
Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 2006;5(1):75–86.PubMedCrossRef
5.
Hoglinger GU, Kassubek J, Csoti I, Ehret R, Herbst H, Wellach I, et al. Differentiation of atypical Parkinson syndromes. J Neural Transm (Vienna). 2017;124(8):997–1004.CrossRef
6.
Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis. 2013;50:42–8.PubMedCrossRef
7.
Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2(1):a009381.PubMedPubMedCentralCrossRef
8.
Tufekci KU, Meuwissen R, Genc S, Genc K. Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol. 2012;88:69–132.PubMedCrossRef
9.
10.
van Dijk KD, Teunissen CE, Drukarch B, Jimenez CR, Groenewegen HJ, Berendse HW, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis. 2010;39(3):229–41.PubMedCrossRefPubMedCentral
11.
Jabbari E, Woodside J, Guo T, Magdalinou NK, Chelban V, Athauda D, et al. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2019;0:1-6.
12.
Aerts MB, Esselink RA, Abdo WF, Meijer FJ, Drost G, Norgren N, et al. Ancillary investigations to diagnose parkinsonism: a prospective clinical study. J Neurol. 2015;262(2):346–56.PubMedCrossRef
13.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591–601.PubMedCrossRef
14.
Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, et al. The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 2016;15(6):546–8.PubMedCrossRef
15.
Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–64.PubMedPubMedCentralCrossRef
16.
Rektor I, Bohnen NI, Korczyn AD, Gryb V, Kumar H, Kramberger MG, et al. An updated diagnostic approach to subtype definition of vascular parkinsonism - recommendations from an expert working group. Parkinsonism Relat Disord. 2018;49:9–16.PubMedCrossRef
17.
Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19(6):630–40.PubMedCrossRef
18.
Abdo WF, Bloem BR, Van Geel WJ, Esselink RAJ, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging. 2007;28(5):742–7.PubMedCrossRef
19.
Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RAJ, Bloem BR, et al. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Front Neurol. 2015;6:91.PubMedPubMedCentralCrossRef
20.
Herbert MK, Eeftens JM, Aerts MB, Esselink RA, Bloem BR, Kuiperij HB, et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord. 2014;20(1):112–5.PubMedCrossRef
21.
Müller M, Kuiperij HB, Claassen JA, Küsters B, Verbeek MM. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging. 2014;35(1):152–8.PubMedCrossRef
22.
Schwenkenbecher P, Janssen T, Wurster U, Konen FF, Neyazi A, Ahlbrecht J, et al. The influence of blood contamination on cerebrospinal fluid diagnostics. Front Neurol. 2019;10(584):1-9.
23.
Lee H, James WS, Cowley SA. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. Biochem Soc Trans. 2017;45(1):131–9.PubMedPubMedCentralCrossRef
24.
Fardell C, Zettergren A, Ran C, Carmine Belin A, Ekman A, Sydow O, et al. S100B polymorphisms are associated with age of onset of Parkinson's disease. BMC Med Genet. 2018;19(1):42.PubMedPubMedCentralCrossRef
25.
Grimes DA, Han F, Panisset M, Racacho L, Xiao F, Zou R, et al. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord. 2006;21(7):906–9.PubMedCrossRef
26.
Chen L, Mo M, Li G, Cen L, Wei L, Xiao Y, et al. The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl Neurodegeneration. 2016;5(16):1-6.
27.
28.
Liu JX, Cao X, Liu Y, Tang FR. CCL28 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus. Neurochem Int. 2012;61(7):1094–101.PubMedCrossRef
29.
Walker DG, Lue L-F, Serrano G, Adler CH, Caviness JN, Sue LI, et al. Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases. Front Neurosci. 2016;9:507.PubMedPubMedCentralCrossRef
30.
Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell. 2016;167(6):1469–80.e12.PubMedPubMedCentralCrossRef
31.
Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, et al. Analysis of gut microbiota in patients with Parkinson's disease. Bull Exp Biol Med. 2017;162(6):734–7.PubMedCrossRef
32.
33.
Yoon JH, Ann EJ, Kim MY, Ahn JS, Jo EH, Lee HJ, et al. Parkin mediates neuroprotection through activation of Notch1 signaling. Neuroreport. 2017;28(4):181–6.CrossRefPubMed
34.
Yamamoto S, Schulze KL, Bellen HJ. Introduction to notch signaling. Methods Mol Biol. 2014;1187:1–14.PubMedCrossRef
35.
Wang TH, Feng ZT, Wei P, Li H, Shi ZJ, Li LY. Effects of pcDNA3-beta-NGF gene-modified BMSC on the rat model of Parkinson's disease. J Mol Neurosci. 2008;35(2):161–9.PubMedCrossRef
36.
Silani V, Pizzuti A, Falini A, Borsani G, Rugarli EI, Melo CA, et al. Beta-nerve growth factor (beta-NGF) mRNA expression in the parkinsonian adrenal gland. Exp Neurol. 1991;113(2):166–70.PubMedCrossRef
37.
Allen SJ, MacGowan SH, Treanor JJ, Feeney R, Wilcock GK, Dawbarn D. Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett. 1991;131(1):135–9.PubMedCrossRef
38.
Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240–7.PubMedCrossRef
39.
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–75.PubMedPubMedCentralCrossRef
40.
Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586.PubMedPubMedCentralCrossRef
41.
Lee W-J, Liao Y-C, Wang Y-F, Lin IF, Wang S-J, Fuh J-L. Plasma MCP-1 and cognitive decline in patients with Alzheimer’s disease and mild cognitive impairment: a two-year follow-up study. Sci Rep. 2018;8(1):1280.PubMedPubMedCentralCrossRef
42.
Sawyer AJ, Tian W, Saucier-Sawyer JK, Rizk PJ, Saltzman WM, Bellamkonda RV, et al. The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation. Biomaterials. 2014;35(25):6698–706.PubMedPubMedCentralCrossRef
43.
Liu W, Gao Y, Chang N. Nurr1 overexpression exerts neuroprotective and anti-inflammatory roles via down-regulating CCL2 expression in both in vivo and in vitro Parkinson's disease models. Biochem Biophys Res Commun. 2017;482(4):1312–9.PubMedCrossRef
44.
Vandivort TC, Birkland TP, Domiciano TP, Mitra S, Kavanagh TJ, Parks WC. Stromelysin-2 (MMP-10) facilitates clearance and moderates inflammation and cell death following lung exposure to long multiwalled carbon nanotubes. Int J Nanomedicine. 2017;12:1019–31.PubMedPubMedCentralCrossRef
Metadata
Title
Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
Authors
Anna Santaella
H. Bea Kuiperij
Anouke van Rumund
Rianne A. J. Esselink
Alain J. van Gool
Bastiaan R. Bloem
Marcel M. Verbeek
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-020-1608-8

Other articles of this Issue 1/2020

BMC Neurology 1/2020 Go to the issue

Research article

Stroke mimics in patients clinically diagnosed with stroke at a tertiary teaching hospital in Tanzania: a prospective cohort study

Research article

Can Samba and Forró Brazilian rhythmic dance be more effective than walking in improving functional mobility and spatiotemporal gait parameters in patients with Parkinson’s disease?

Research article

A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy

Research article

Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018

Case report

Mechanical Thrombectomy of COVID-19 positive acute ischemic stroke patient: a case report and call for preparedness

Case report

Disseminated Cryptococcosis revealed by transverse myelitis in Immunocompetent patient: a case report and review of the literature